반응식
[F:1][C:2]([F:7])([F:6])[C:3]([OH:5])=[O:4].[CH2:8]([S:10]([N:13]1[CH2:18][CH2:17][CH:16]([C:19]2[C:27]3[C:22](=[C:23]([C:39]([NH2:41])=[O:40])[CH:24]=[C:25]([C:28]4S[C:30]([CH:33]5[CH2:38][NH:37][CH2:36][CH2:35][NH:34]5)=[CH:31][CH:32]=4)[CH:26]=3)[NH:21][CH:20]=2)[CH2:15][CH2:14]1)(=[O:12])=[O:11])[CH3:9].Br[C:43]1SC(C2CNCCN2)=C[CH:44]=1>>[F:1][C:2]([F:7])([F:6])[C:3]([OH:5])=[O:4].[CH2:8]([S:10]([N:13]1[CH2:14][CH2:15][CH:16]([C:19]2[C:27]3[C:22](=[C:23]([C:39]([NH2:41])=[O:40])[CH:24]=[C:25]([C:28]4[CH:32]=[CH:31][C:30]([CH:33]5[CH2:38][NH:37][CH2:36][CH2:35][NH:34]5)=[CH:44][CH:43]=4)[CH:26]=3)[NH:21][CH:20]=2)[CH2:17][CH2:18]1)(=[O:11])=[O:12])[CH3:9]참가 물질
3
반응물 2
생성물 1
실험 절차
The title compound was prepared according to the general procedure of 3-[1-(ethylsulfonyl)-4-piperidinyl]-5-[5-(2-piperazinyl)-2-thienyl]-1H-indole-7-carboxamide trifluoroacetate, substituting 2-(4-bromophenyl)piperazine (94 mg, 0.39 mmol) for 2-(5-bromo-2-thienyl)piperazine to afford 20.5 mg of the title compound (25.9%).
후처리
- customThe title compound was prepared
출처 및 근거
- ORD 기록
- ord-25819822f188489b9d71177f0c149c92
- 출처 데이터셋
- uspto-grants-2011_11
- 특허 번호
- US08063071B2
연결된 노트
불러오는 중…